Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study
Minoru Kato(Osaka International Cancer Institute), Naotaka Nishiyama(University of Toyama), Taketo Kawai(National Center for Global Health and Medicine), Sho Sekito(Aichi Cancer Center), Taisuke Matsue(Osaka Metropolitan University), Tomokazu Sazuka(Chiba University), Fumihiko Urabe(Jikei University School of Medicine), Keiji Yasue(Higashi Nagoya National Hospital), Wataru Fukuokaya(Jikei University School of Medicine), Yoshiyuki Matsui(Tokyo National Hospital), Shuichi Tatarano(Kagoshima University), Jun Miki(Jikei University School of Medicine), Katsuyoshi Hashine(Shikoku Cancer Center), Takeshi Sano(Tokushima University), Kenichiro Shiga(Harasanshin Hospital), Yusuke Sugino(Mie University), Rikiya Taoka(Kagawa University), Takuji Hayashi(Osaka International Cancer Institute), Koichiro Wada(Shimane University), Junichi Inokuchi(Kyushu University), Hiroaki Matsumoto(Yamaguchi University), Soki Kashima(Akita University), Makito Miyake(Nara Medical University), Kiyoaki Nishihara(Kurume University), Yuto Matsushita(Hamamatsu University School of Medicine), Yoji Murakami(Kumamoto University), Ryoichi Saito(University of Miyazaki), Shoma Yamamoto(Hyogo Medical University), Hirohito Naito(Kagawa University), Noriya Yamaguchi(Tottori University), Hiroyuki Nishiyama(University of Tsukuba), Shotaro Nakanishi(University of the Ryukyus), Kei Daizumoto(Tokushima University), Takashige Abe(Hokkaido University), Ayumu Matsuda(Tokyo National Hospital), Shingo Yamamoto(Hyogo University), Takashi Kawahara(University of Tsukuba), Hiroshi Kitamura(University of Toyama), Shingo Hatakeyama(Hirosaki University), Masato Fujii(Niigata University), Junji Uchida(Osaka Prefectural Medical Center), Ryo Maruyama(Niigata University)
Cited by 3
Related Papers
The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy
|The Journal of Experimental Medicine|2004|631
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412